Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Prospective, observational pilot study of ten post-transplant patients presenting with
diarrhea while taking Mycophenolate Mofetil (MMF). These patients will undergo a standard
workup to confirm MMF induced diarrhea. A stool fecal calprotectin will be measured to
determine if it may be helpful in confirming the diagnosis of MMF associated diarrhea. Once
the diagnosis is confirmed, the patients will then be treated with a short course of
subcutaneous Octreotide which has been shown to cure this type of diarrhea.